Chromocell Therapeutics Corporation (CHRO)
USD 1.35
(-1.01%)
USD 1.35
(-1.01%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.38 Million USD | -200.2% |
| 2022 | -2.45 Million USD | -312.94% |
| 2021 | -595.38 Thousand USD | 9.87% |
| 2020 | -660.58 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.77 Million USD | 30.86% |
| 2024 Q1 | -2.56 Million USD | 36.56% |
| 2023 Q3 | -1.42 Million USD | -49.13% |
| 2023 Q1 | -966.56 Thousand USD | -30.69% |
| 2023 FY | -7.38 Million USD | -200.2% |
| 2023 Q2 | -953.34 Thousand USD | 1.37% |
| 2023 Q4 | -4.03 Million USD | -184.1% |
| 2022 Q4 | -739.58 Thousand USD | -32.86% |
| 2022 FY | -2.45 Million USD | -312.94% |
| 2022 Q3 | -556.65 Thousand USD | -66.64% |
| 2022 Q2 | -334.05 Thousand USD | -7.6% |
| 2022 Q1 | -310.45 Thousand USD | 0.0% |
| 2021 FY | -595.38 Thousand USD | 9.87% |
| 2020 FY | -660.58 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | 74.516% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | 14.495% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 89.31% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | 84.881% |
| Azitra, Inc. | -11.28 Million USD | 34.589% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | 3.317% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | 74.737% |
| CEL-SCI Corporation | -32.36 Million USD | 77.196% |
| iBio, Inc. | -24.9 Million USD | 70.367% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | 65.648% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | 62.672% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | 67.828% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | 51.369% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | 23.436% |
| NanoViricides, Inc. | -8.29 Million USD | 11.012% |
| Oragenics, Inc. | -20.65 Million USD | 64.268% |
| BiomX Inc. | -26.16 Million USD | 71.796% |
| BiomX Inc. | -26.16 Million USD | 71.796% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 188.797% |
| Palatin Technologies, Inc. | -29.73 Million USD | 75.179% |
| Scorpius Holdings, Inc. | -45.21 Million USD | 83.677% |
| Theriva Biologics, Inc. | -18.34 Million USD | 59.776% |